SCHEMBL4128211

SCHEMBL4128211

COC(=O)C(C)(C)OCC(=O)NCCC#N

nearest known ligand 0.41

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.37
HSD17B10 Q99714 1/20 0.35
MCL1 Q07820 2/20 0.35
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4117711 0.82 HSD17B10 (0.37) MAPTHSD17B10MCL1MEN1KMT2A
SCHEMBL13261163 0.71 MAPT (0.44) MAPTHSD17B10MCL1MEN1KMT2A
SCHEMBL13305942 0.69 MEN1 (0.38) MEN1KMT2A
SCHEMBL19169457 0.68 MAPT (0.49) MAPTHSD17B10MCL1MEN1KMT2A
SCHEMBL10244410 0.68
SCHEMBL6360689 0.68
SCHEMBL2015627 0.68 MGAM (0.37) MAPTKMT2A
SCHEMBL4128811 0.68 TSHR (0.39) MAPTHSD17B10KMT2A
SCHEMBL48475 0.67
SCHEMBL1887418 0.67 MEN1 (0.36) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR MAPT 4428/4885HSD17B10 45/4885MCL1 4015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.